J. Rick Turner, PhD, PGCE, MICR, is Chairman, Department of Clinical Research at Campbell University School of Pharmacy. Dr. Turner has extensive teaching, research, and pharmaceutical credentials and more than a dozen awards and honors, including a Commit to Product Development Award from GlaxoSmithKline. He is the author of seven books and more than 100 journal articles and published abstracts. Todd A. Durham, MS, is Senior Director of Biostatistics and Data Management at Inspire Pharmaceuticals. Prior to joining Inspire, Mr. Durham served as Associate Director of Biostatistics at Quintiles, Inc. Mr. Durham has made significant statistical contributions to six NDA submissions and has been involved with five presentations to FDA advisory committees.

“This fills the void for a book addressing the safety issues, especially cardiac safety issues, of therapeutic agents in development. The content is high yield, easy to understand and succinct, covering the multiple steps involved in the drug safety and approval process.” (Doody's, April 2009)

• Foreword. Preface.Acknowledgments.Abbreviations.Part I: INTRODUCTION.1. The Importance of Cardiac Safety Assessments.2. The Biological Basis of Adverse Drug Reactions.Part II: CARDIAC FUNCTION AND PATHOLOGY.3. Cardiac Structure and Function.4. Cardiac Pathophysiology and Disease.SECTION III: DRUG DISCOVERY AND NONCLINICAL DEVELOPMENT.5. Drug Discovery and Drug Design.6. Nonclinical Development.SECTION IV: PREAPPROVAL CLINICAL DEVELOPMENT.7. The Thorough QT/QTc Trial.8. General Safety Assessments.SECTION V: POSTMARKETING ASSESSMENT METHODOLOGIES.9. Therapeutic Use Trials and Meta-analyses.10. Assessment Methodologies in Nonexperimental Postmarketing Surveillance.11. Postmarketing Proarrythmic Cardiac Safety Assessments.12. Generalized Cardiac Safety.SECTION VI: BEHAVIORAL DRUG SAFETY.13. Medication Errors, Adherence, and Concordance.SECTION VII: INTEGRATIVE DISCUSSION.14. Future Directions in Drug Safety.References.Index.

J. Rick Turner, PhD, PGCE, MICR, is Chairman, Department of Clinical Research at Campbell University School of Pharmacy. Dr. Turner has extensive teaching, research, and pharmaceutical credentials and more than a dozen awards and honors, including a Commit to Product Development Award from GlaxoSmithKline. He is the author of seven books and more than 100 journal articles and published abstracts. Todd A. Durham, MS, is Senior Director of Biostatistics and Data Management at Inspire Pharmaceuticals. Prior to joining Inspire, Mr. Durham served as Associate Director of Biostatistics at Quintiles, Inc. Mr. Durham has made significant statistical contributions to six NDA submissions and has been involved with five presentations to FDA advisory committees.

“This fills the void for a book addressing the safety issues, especially cardiac safety issues, of therapeutic agents in development. The content is high yield, easy to understand and succinct, covering the multiple steps involved in the drug safety and approval process.” (Doody's, April 2009)

• Foreword. Preface.Acknowledgments.Abbreviations.Part I: INTRODUCTION.1. The Importance of Cardiac Safety Assessments.2. The Biological Basis of Adverse Drug Reactions.Part II: CARDIAC FUNCTION AND PATHOLOGY.3. Cardiac Structure and Function.4. Cardiac Pathophysiology and Disease.SECTION III: DRUG DISCOVERY AND NONCLINICAL DEVELOPMENT.5. Drug Discovery and Drug Design.6. Nonclinical Development.SECTION IV: PREAPPROVAL CLINICAL DEVELOPMENT.7. The Thorough QT/QTc Trial.8. General Safety Assessments.SECTION V: POSTMARKETING ASSESSMENT METHODOLOGIES.9. Therapeutic Use Trials and Meta-analyses.10. Assessment Methodologies in Nonexperimental Postmarketing Surveillance.11. Postmarketing Proarrythmic Cardiac Safety Assessments.12. Generalized Cardiac Safety.SECTION VI: BEHAVIORAL DRUG SAFETY.13. Medication Errors, Adherence, and Concordance.SECTION VII: INTEGRATIVE DISCUSSION.14. Future Directions in Drug Safety.References.Index.

J. Rick Turner, PhD, PGCE, MICR, is Chairman, Department of Clinical Research at Campbell University School of Pharmacy. Dr. Turner has extensive teaching, research, and pharmaceutical credentials and more than a dozen awards and honors, including a Commit to Product Development Award from GlaxoSmithKline. He is the author of seven books and more than 100 journal articles and published abstracts. Todd A. Durham, MS, is Senior Director of Biostatistics and Data Management at Inspire Pharmaceuticals. Prior to joining Inspire, Mr. Durham served as Associate Director of Biostatistics at Quintiles, Inc. Mr. Durham has made significant statistical contributions to six NDA submissions and has been involved with five presentations to FDA advisory committees.

“This fills the void for a book addressing the safety issues, especially cardiac safety issues, of therapeutic agents in development. The content is high yield, easy to understand and succinct, covering the multiple steps involved in the drug safety and approval process.” (Doody's, April 2009)

• Foreword. Preface.Acknowledgments.Abbreviations.Part I: INTRODUCTION.1. The Importance of Cardiac Safety Assessments.2. The Biological Basis of Adverse Drug Reactions.Part II: CARDIAC FUNCTION AND PATHOLOGY.3. Cardiac Structure and Function.4. Cardiac Pathophysiology and Disease.SECTION III: DRUG DISCOVERY AND NONCLINICAL DEVELOPMENT.5. Drug Discovery and Drug Design.6. Nonclinical Development.SECTION IV: PREAPPROVAL CLINICAL DEVELOPMENT.7. The Thorough QT/QTc Trial.8. General Safety Assessments.SECTION V: POSTMARKETING ASSESSMENT METHODOLOGIES.9. Therapeutic Use Trials and Meta-analyses.10. Assessment Methodologies in Nonexperimental Postmarketing Surveillance.11. Postmarketing Proarrythmic Cardiac Safety Assessments.12. Generalized Cardiac Safety.SECTION VI: BEHAVIORAL DRUG SAFETY.13. Medication Errors, Adherence, and Concordance.SECTION VII: INTEGRATIVE DISCUSSION.14. Future Directions in Drug Safety.References.Index.